BiotechTube

EPO906 epothilone B

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoid

Conditions

Carcinoid, Neuroendocrine Tumors

Trial Timeline

Jul 1, 2002 → Apr 1, 2007

NCT ID
NCT00050349

About EPO906 epothilone B

EPO906 epothilone B is a phase 2 stage product being developed by Novartis for Carcinoid. The current trial status is completed. This product is registered under clinical trial identifier NCT00050349. Target conditions include Carcinoid, Neuroendocrine Tumors.

What happened to similar drugs?

1 of 9 similar drugs in Carcinoid were approved

Approved (1) Terminated (1) Active (7)
✅lanreotide (Autogel formulation)IpsenApproved
🔄Pasireotide + OctreotideNovartisPhase 3
🔄Octreotide + Placebo + EverolimusNovartisPhase 3
❌lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
🔄Lanreotide + PlaceboIpsenPhase 3
🔄Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
🔄Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00050349Phase 2Completed

Competing Products

20 competing products in Carcinoid

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Somatostatin AnalogEli LillyPhase 2
35
PasireotideNovartisPhase 1
29
Pasireotide + OctreotideNovartisPhase 3
40
Pasireotide (SOM230)NovartisPhase 2
35
Octreotide + Placebo + EverolimusNovartisPhase 3
40
LutatheraNovartisPhase 2
27
PanitumumabAmgenPhase 2
27
AxitinibPfizerPhase 2
35
Lanreotide + Placebo (for sunitinib) + SunitinibPfizerPhase 2
31
Nivolumab + CabozantinibBristol Myers SquibbPhase 2
35
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatinSanofiPhase 2/3
30
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
29
lanreotide (Autogel formulation)IpsenApproved
40
Lanreotide + PlaceboIpsenPhase 3
37
BIM 23A760IpsenPhase 2
24
Randomized: 40 mg Paltusotine + Randomized: 80 mg PaltusotineCrinetics PharmaceuticalsPhase 2
32
Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
44
Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
34
Telotristat etiprateLexicon PharmaceuticalsPhase 3
34
500 mg [14C]-LX1606Lexicon PharmaceuticalsPhase 1
23